Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked reticulate pigmentary disorder is an extremely rare skin disease described in only four families to date and characterized in males by diffuse reticulate brown hyperpigmentated skin lesions developing in early childhood and a variety of systemic manifestations (recurrent pneumonia, corneal opacification, gastrointestinal inflammation, urethral stricture, failure to thrive, hypohidrosis, digital clubbing, and unruly hair and flared eyebrows), while in females, there is only cutaneous involvement with the development in early childhood of localized brown hyperpigmented skin lesions following the lines of Blaschko. This disease was first considered as a cutaneous amyloidosis, but amyloid deposits are an inconstant feature.
Features include always present findings: Failure to thrive in infancy, Photophobia, Recurrent pneumonia, and Reticular hyperpigmentation and others; and very common findings: Bronchiectasis. 23 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 3 | Reticular hyperpigmentation, Decreased sweating (hypohidrosis), Thickened, rough skin (hyperkeratosis) |
POLA1 function has not been fully characterized.
X-linked reticulate pigmentary disorder has been associated with mutations in the POLA1 gene on chromosome X.
Genetic testing for POLA1 is available. Testing is considered supportive for diagnosis.
Phenotype severity distribution: 6 always present features, 1 very common feature, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for X-linked reticulate pigmentary disorder.
3 publications have been identified in PubMed for X-linked reticulate pigmentary disorder. Research spans Review / Meta-Analysis (67%) and Other (33%).
Mohapatra L (2024). [PMID: 39139099](https://pubmed.ncbi.nlm.nih.gov/39139099/). *Clin Exp Dermatol*. [Review / Meta-Analysis]
Tummala H (2024). [PMID: 39198715](https://pubmed.ncbi.nlm.nih.gov/39198715/). *EMBO Mol Med*. [Review / Meta-Analysis]
Zhang Y (2024). [PMID: 39635787](https://pubmed.ncbi.nlm.nih.gov/39635787/). *Indian J Dermatol Venereol Leprol*. [Other]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 6:21 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked reticulate pigmentary disorder
Digestive system |
2 |
Colitis, Chronic diarrhea |
Eyes | 2 | Corneal scarring, Visual impairment |
Lungs and breathing | 2 | Recurrent pneumonia, Bronchiectasis |
Brain and nerves | 2 | Intellectual disability, Global developmental delay |
Growth and development | 1 | Failure to thrive in infancy |
Lab test results | 1 | Increased circulating interleukin 8 concentration |